- Home
- APLM vs SNGX Comparison
APLM vs SNGX Comparison
Compare APLM & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- SNGX
- Stock Information
- Founded
- APLM 2016
- SNGX 1987
- Country
- APLM United States
- SNGX United States
- Employees
- APLM N/A
- SNGX N/A
- Industry
- APLM Blank Checks
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- APLM Finance
- SNGX Health Care
- Exchange
- APLM Nasdaq
- SNGX Nasdaq
- Market Cap
- APLM 7.7M
- SNGX 6.5M
- IPO Year
- APLM N/A
- SNGX 1987
- Fundamental
- Price
- APLM $6.56
- SNGX $2.17
- Analyst Decision
- APLM Strong Buy
- SNGX
- Analyst Count
- APLM 1
- SNGX 0
- Target Price
- APLM $200.00
- SNGX N/A
- AVG Volume (30 Days)
- APLM 57.9K
- SNGX 198.8K
- Earning Date
- APLM 04-03-2025
- SNGX 05-09-2025
- Dividend Yield
- APLM N/A
- SNGX N/A
- EPS Growth
- APLM N/A
- SNGX N/A
- EPS
- APLM N/A
- SNGX N/A
- Revenue
- APLM $198,000.00
- SNGX $119,371.00
- Revenue This Year
- APLM $415.15
- SNGX N/A
- Revenue Next Year
- APLM N/A
- SNGX N/A
- P/E Ratio
- APLM N/A
- SNGX N/A
- Revenue Growth
- APLM N/A
- SNGX N/A
- 52 Week Low
- APLM $4.71
- SNGX $1.68
- 52 Week High
- APLM $49.00
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- APLM 50.05
- SNGX 52.69
- Support Level
- APLM $5.41
- SNGX $1.97
- Resistance Level
- APLM $6.19
- SNGX $2.21
- Average True Range (ATR)
- APLM 0.76
- SNGX 0.15
- MACD
- APLM 0.10
- SNGX 0.03
- Stochastic Oscillator
- APLM 86.05
- SNGX 86.96
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).